▼Naltrexone/bupropion for obesity

@article{2017NaltrexonebupropionFO,
  title={▼Naltrexone/bupropion for obesity},
  author={},
  journal={Drug and Therapeutics Bulletin},
  year={2017},
  volume={55},
  pages={126 - 129}
}
  • Published 2017
  • Medicine
  • Drug and Therapeutics Bulletin
    • ▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy. 
    View on BMJ
    ncbi.nlm.nih.gov

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    References

    SHOWING 1-10 OF 30 REFERENCES
    Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
    • Medicine
    • Prescrire international
    • 2015
    • 2
    ▾ Liraglutide for weight management
    • 5
    Role of Bupropion Plus Naltrexone for the Management of Obesity
    • 1
    Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
    • 53
    • PDF
    A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
    • 314
    The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
    • 11
    • PDF
    Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    • 527
    Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial
    • 332
    • PDF
    Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
    • 220
    • PDF
    Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    • 91
    • PDF